Search PubMed⌕ Search

Biomedical subjects

F Pedersen

Publications and source records attributed to F Pedersen.

At least 73 records · Page 4Linked to original sources
PubMed1984

The effect of alprenolol on serum myoglobin levels in acute myocardial infarction.

In a group of 37 patients with definite acute myocardial infarction (AMI) allocated to treatment with either alprenolol (n = 20) or placebo (n = 17) serial determinations of concentrations in serum of myoglobin (S-Mb), creatine kinase (S-CK), aspartate aminotransferase (S-ASAT) and lactate dehydrogenase (S-LDH) were performed. The median peak levels of S-Mb, S-CK and S-LDH were significantly (P less than 0.05) lower among patients treated with alprenolol. The median of the estimated infarct size based on S-CK curves was also significantly (P less than 0.01) lower in the alprenolol group. There was no significant difference between the estimated infarct size based on S-Mb values in the two groups. It is concluded that the present study provides indirect evidence for the assumption that early beta-blockade in AMI can reduce infarct size.

Adult↗
PubMed1983

Transcobalamin II as an indicator of activity in metastatic renal adenocarcinoma.

Transcobalamin (TC) II, the cellular membrane carrier of vitamin B 12 has recently attracted attention as an acute phase reactant in autoimmune disorders and reticuloendothelial malignancies. In a prospective clinical evaluation, 20 patients presenting with proven metastatic renal adenocarcinoma underwent nephrectomy and were followed till death, or at least 3 years. Two patients obtained a complete remission. TCII was significantly elevated (P less than 0.005) preoperatively and varied with activity of the carcinoma, supplementing the erythrocyte sedimentation rate and fibrinogen. The postoperative response and pattern of TCII activity correlated with disease progression. No relation was found to liver metastases. This study supports the recent findings of TCII as an indicator of activity in disorders affecting the immune mechanisms probably acting as an acute phase reactant, and is a useful supplement in renal adenocarcinoma.

Adenocarcinoma↗
PubMed1983

Systolic time intervals during long-term beta-blockade with alprenol in ischaemic heart disease.

The effect of long-term treatment with alprenolol on left ventricular function was investigated in a controlled double-blind study of 15 patients with ischaemic heart disease (alprenolol 6, placebo 9), by measurement of systolic time intervals (STI). Significant prolongation of QS2I was observed in patients treated with alprenolol (p less than 0.05), while changes in PEPI, LVETI and PEP/LVET were all insignificant. The heart rate x systolic blood pressure product (RPP) was significantly reduced in the alprenolol group (p less than 0.05). The data suggest that long-term treatment with alprenolol did not impair left ventricular function as evaluated by STI, and that myocardial oxygen demand, assessed by RPP, was reduced during the treatment.

Aged↗
PubMed1979

Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results.

A double-blind study of alprenolol versus placebo was done in patients with definite or suspected myocardial infarction to show the effect of the drug on mortality-rate after a year of treatment in patients aged less than or equal to 65 and to study the tolerance of the drug by patients greater than 65 years of age. The dose given was 5--10 mg intravenously, followed by 200 mg twice a day, orally. Patients in whom beta-blockade was contraindicated were excluded. All deaths, side-effects, and dropouts were recorded. Of the 480 patients in the study, 238 patients received alprenolol and 242 placebo. During the year of follow-up 108 patients dropped out from the study. Mortality was not reduced in patients greater than 65 years of age. In those less than or equal to 65 years alprenolol significantly reduced mortality-rate (20% mortality in placebo group vs 9% in treated group). There was also a significant reduction in mortality-rate among those with definite infarction (28% in the placebo vs 15% in the treated group).

Acute Disease↗
PubMed1976

On acid-base problems in REDY dialysis.

The acid-base status of dialysate and blood during REDY dialysis has been studied. A very low pH (6,90) has been found in the venous blood. However, the predialytic acidosis of the patients is corrected, which is attributed to the acetate supply during dialysis. It is pointed out that the implications of the low venous blood pH are still inadequately investigated.

Acetates↗